| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 23048 |
| Drug | Fenfluramine (Fintepla®) |
| Brand | Fintepla® |
| Indication | Fenfluramine (Fintepla®) is indicated for seizures associated with Dravet Syndrome (as an add-on therapy for patients two years of age and older). |
| Assessment Process | |
| Rapid review commissioned | 31/07/2023 |
| Rapid review completed | 07/09/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of fenfluramine compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 29/09/2023 |
| Pre-submission consultation with Applicant | 07/11/2023 |
| Full submission received from Applicant | 16/05/2024 |
| Preliminary review sent to Applicant | 20/05/2024 |
| NCPE assessment re-commenced | 17/06/2024 |
| Factual accuracy sent to Applicant | 26/06/2024 |
| NCPE assessment re-commenced | 02/07/2024 |
| NCPE assessment completed | 03/07/2024 |
| NCPE assessment outcome | The NCPE recommends that fenfluramine be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments.* |
*This recommendation should be considered while also having regards to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
